State Street Corp raised its stake in shares of Puma Biotechnology Inc (NYSE:PBYI) by 113.1% during the fourth quarter, Holdings Channel reports. The fund owned 1,946,098 shares of the biopharmaceutical companys stock after buying an additional 1,032,915 shares during the period. State Street Corp owned about 0.05% of Puma Biotechnology worth $59,746,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. BlackRock Advisors LLC raised its position in Puma Biotechnology by 289.2% in the third quarter. BlackRock Advisors LLC now owns 54,120 shares of the biopharmaceutical companys stock valued at $3,629,000 after buying an additional 40,214 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Puma Biotechnology by 2.4% in the third quarter. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical companys stock valued at $864,000 after buying an additional 300 shares during the last quarter. CAM Group Holding A S acquired a new position in Puma Biotechnology during the third quarter valued at approximately $2,012,000. Bank of New York Mellon Corp raised its position in Puma Biotechnology by 41.6% in the third quarter. Bank of New York Mellon Corp now owns 158,443 shares of the biopharmaceutical companys stock valued at $10,623,000 after buying an additional 46,525 shares during the last quarter. Finally, Smith Asset Management Group LP acquired a new position in Puma Biotechnology during the third quarter valued at approximately $371,000. 80.98% of the stock is owned by institutional investors and hedge funds.

Shares of Puma Biotechnology Inc (NYSE:PBYI) opened at 41.80 on Wednesday. Puma Biotechnology Inc has a one year low of $19.74 and a one year high of $73.27. The company has a 50-day moving average of $35.92 and a 200 day moving average of $43.82. The firms market cap is $1.54 billion.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) EPS for the quarter, missing the Zacks consensus estimate of ($1.92) by $0.12. On average, equities research analysts expect that Puma Biotechnology Inc will post ($8.32) EPS for the current fiscal year.

Several research analysts have recently commented on the stock. Stifel Nicolaus reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, November 30th. Royal Bank of Canada reissued a sector perform rating on shares of Puma Biotechnology in a research note on Wednesday, November 16th. Cowen and Company reissued a market perform rating on shares of Puma Biotechnology in a research note on Tuesday, November 15th. Credit Suisse Group AG reissued an outperform rating and issued a $111.00 price objective on shares of Puma Biotechnology in a research note on Tuesday, November 15th. Finally, Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the companys stock. The stock currently has an average rating of Hold and an average target price of $73.50.

In other news, SVP Richard Paul Bryce sold 2,293 shares of the companys stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $33.24, for a total transaction of $76,219.32. Following the completion of the transaction, the senior vice president now owns 29,237 shares of the companys stock, valued at approximately $971,837.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Robert Charnas sold 3,008 shares of the companys stock in a transaction dated Wednesday, February 1st. The shares were sold at an average price of $31.83, for a total transaction of $95,744.64. Following the transaction, the insider now directly owns 28,461 shares of the companys stock, valued at approximately $905,913.63. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,503 shares of company stock valued at $511,078. Corporate insiders own 22.70% of the companys stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

See the original post here:
The State Street Corp Acquires 1032915 Shares of Puma Biotechnology Inc (PBYI) - Petro Global News 24